These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25457851)

  • 21. New treatments for ulcerative colitis: do we have pediatric data?
    Russell RK; Hansen R; Turner D
    Expert Rev Clin Immunol; 2016 Jul; 12(7):701-4. PubMed ID: 27074695
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
    Zoet ID; de Boer NK; de Meij TG
    J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
    [No Abstract]   [Full Text] [Related]  

  • 23. Mirikizumab for the Management of Ulcerative Colitis.
    Venkateswaran N
    Gastroenterology; 2024 Apr; 166(4):710. PubMed ID: 37926125
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland].
    Iwańczak B; Ryzko J; Kierkuś J; Jankowski P; Sładek M; Wasilewska A; Landowski P; Szczepanik M; Krzesiek E; Sienkiewicz E; Szaflarska-Popławska A; Wiecek S; Kwiecien J; Kacperska M; Korczowski B; Maślana J
    Pol Merkur Lekarski; 2014 May; 36(215):311-5. PubMed ID: 24964507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
    Lobatón T; Truyens M
    Aliment Pharmacol Ther; 2023 Aug; 58(3):359-360. PubMed ID: 37452596
    [No Abstract]   [Full Text] [Related]  

  • 26. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Baert F; Vande Casteele N; Tops S; Noman M; Van Assche G; Rutgeerts P; Gils A; Vermeire S; Ferrante M
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1324-32. PubMed ID: 25277873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. 21-15 May 2006, Los Angeles, CA, USA.
    Aylett P
    IDrugs; 2006 Jul; 9(7):452-4. PubMed ID: 16821150
    [No Abstract]   [Full Text] [Related]  

  • 30. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Kim JH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):162-3. PubMed ID: 26934881
    [No Abstract]   [Full Text] [Related]  

  • 31. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs.
    Romano C; Sinagra E; Criscuoli V; Orlando A; Maisano S; Cottone M
    J Crohns Colitis; 2013 Oct; 7(9):e405-6. PubMed ID: 23764367
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and Safety of Etrolizumab in the Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jaber F; Alsakarneh S; Ayyad M; Alsharaeh T; Salahat AJ; Jaber M; Kilani Y; Aldiabat M; Gangwani MK; Abboud Y; Fares A; Dahiya DS; Ahmed M; Shukla R
    Am J Ther; 2024 Sep-Oct 01; 31(5):e596-e600. PubMed ID: 39292841
    [No Abstract]   [Full Text] [Related]  

  • 34. Positioning Therapy for Ulcerative Colitis.
    Grinspan A; Kornbluth A
    Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of inflammatory bowel disease: past, present and future.
    Keyashian K; Annunziata ML; Sakuraba A; Hanauer S
    Expert Rev Clin Immunol; 2012 May; 8(4):303-5. PubMed ID: 22607175
    [No Abstract]   [Full Text] [Related]  

  • 39. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
    Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
    Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.